03.11.2025

On November 3, President of the Republic of Uzbekistan Shavkat Mirziyoyev got acquainted with the presentation on improving medical care for children with rare diseases, reform process and implementation of new projects in the sphere of pharmaceuticals. 

Uzbekistan is consistently implementing measures to prevent hereditary and congenital diseases, as well as to ensure timely diagnosis and treatment of children with rare (orphan) disorders.

Currently, 2,174 children suffering from five types of orphan and hereditary genetic diseases receive free diagnostics, medications, and specialized nutrition funded by the state budget.

As diagnostic quality improves, new types of rare diseases are being identified, increasing the number of children requiring treatment and support.

A program for 2026-2030 has been developed to strengthen medical and social assistance for children with rare and hereditary genetic diseases. Under this program, the number of conditions covered by state funding will increase from five to ten, and the age limit for beneficiaries will be extended from 18 to 21 years.

A total of 961 billion soums will be allocated for its implementation. The President signed a decree approving the program. 

The Head of State signed the corresponding decree and approved the program.

The President was also briefed on the development of the pharmaceutical industry, investment attraction, the implementation of projects within the “Tashkent Pharma Park” industrial zone, and ongoing efforts to ensure the quality and safety of medicines.

Enterprises in the sector produced goods worth 5 trillion soums, exported products valued at $172 million, and attracted $286 million in investments, including $257 million in foreign investments.

35 domestic companies have launched the production of 205 types of medicines, with exports reaching 55 countries. This year alone, 16 projects worth a total of $29 million have been commissioned, creating 830 new jobs.

To ensure quality and safety, the GMP standard has been introduced at 61 enterprises, GDP at 486 distribution warehouses, and GPP at 9,450 pharmacies

The presentation also addressed measures to prevent price manipulation in setting reference prices for imported medicines.

Currently, out of 7,600 imported drug types, 4,900 are not included in the reference price lists of benchmark countries. Under the proposed measures, starting from January 1, 2026, the average prices of 2,600 prescription drugs are expected to drop by 40–50 percent.

Issues on improving public procurement mechanisms for pharmaceuticals were also reviewed. To eliminate low-quality products and corruption risks, all procurements will be conducted through the specialized online platform farma.xarid.uz.

Once the system is launched, only manufacturers, distributors, and suppliers with the required certifications (GMP, ISO:13485, GDP) will be eligible to participate.

The volumes of public procurement and the registries of certified manufacturers and distributors will be made publicly accessible.

The system will feature an automated mechanism to ensure that the purchase prices of medicines do not exceed the established reference level.

The President instructed to develop, by January 1, 2026, a dedicated platform to identify the needs of public medical institutions for medicines and medical equipment, and to manage inventory more effectively.

Information was also presented on the new procedure for state registration of medicines and medical devices.

The new mechanism provides for technology transfer–based production, enabling foreign pharmaceutical companies to manufacture products using local facilities and obtain state registration through an accelerated process.

Conditions are being created to introduce new types of biotechnological and cellular preparations into medical practice aimed at treating damaged tissues, growing individual organs, and restoring the body’s functional capabilities.

Clinical trials of generics and the evaluation of their results will be conducted in line with international standards, while registration timelines for such medicines will be shortened. Medical devices of the first safety class (except sterile, measuring, and invasive ones) will be exempt from laboratory and clinical testing.

President Shavkat Mirziyoyev approved the presented proposals and instructed to fully implement 32 investment projects worth $166 million by the end of 2025, create 1,500 new jobs, increase production and export volumes, and reduce prices for prescription medicines.